PWM
EW icon

Parkworth Wealth Management’s Edwards Lifesciences EW Stock Holding History

Parkworth Wealth Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$1.41K Buy
18
+12
+200% +$895 ﹤0.01% 332
2025
Q1 		$435 Hold
6
– – ﹤0.01% 466
2024
Q4 		$444 Buy
+6
New +$420 ﹤0.01% 469

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Parkworth Wealth Management's EW Position: Q2 2025 in Review

Parkworth Wealth Management increased its Edwards Lifesciences (EW) stake by 200% in Q2 2025, buying an estimated $895 and bringing the position to 18 shares worth $1.41K. The position accounts for ﹤0.01% of the portfolio, ranked #332.

Parkworth Wealth Management first reported a position in EW in Q4 2024 and has held it in 3 quarters since. 1,259 funds tracked by Wall St. Rank hold EW as of Q2 2025.

  • Parkworth Wealth Management held 18 shares of Edwards Lifesciences worth $1.41K as of Q2 2025.
  • Parkworth Wealth Management bought 12 Edwards Lifesciences shares in Q2 2025, an estimated $895.
  • Edwards Lifesciences made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #332 holding.
  • Parkworth Wealth Management first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 3 quarters since.
  • 1,259 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.